CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance
ACS Infectious Diseases · 14.07.2023 · 9 (7) · 1283-1302
DOI: 10.1021/acsinfecdis.2c00649 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Infectious Diseases, online erschienen am 22.06.2023. Verfasst von Arianna Mayorga-Ramos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Biomédica (CENBIO), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito 170527, Ecuador. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Anti-Infective Agents. Die Arbeit wurde bisher 222-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The emergence of antibiotic-resistant bacterial strains is a source of public health concern across the globe. As the discovery of new conventional antibiotics has stalled significantly over the past decade, there is an urgency to develop novel approaches to address drug resistance in infectious diseases. The use of a CRISPR-Cas-based system for the precise elimination of targeted bacterial populations holds promise as an innovative approach for new antimicrobial agent design. The CRISPR-Cas targeting system is celebrated for its high versatility and specificity, offering an excellent opportunity to fight antibiotic resistance in pathogens by selectively inactivating genes involved in antibiotic resistance, biofilm formation, pathogenicity, virulence, or bacterial viability. The CRISPR-Cas strategy can enact antimicrobial effects by two approaches: inactivation of chromosomal genes or curing of plasmids encoding antibiotic resistance. In this Review, we provide an overview of the main CRISPR-Cas systems utilized for the creation of these antimicrobials, as well as highlighting promising studies in the field. We also offer a detailed discussion about the most commonly used mechanisms for CRISPR-Cas delivery: bacteriophages, nanoparticles, and conjugative plasmids. Lastly, we address possible mechanisms of interference that should be considered during the intelligent design of these novel approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigación Biomédica (CENBIO), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito 170527, Ecuador.
- Escuela de Medicina, Colegio de Ciencias de la Salud Quito, Universidad San Francisco de Quito USFQ, Quito 170902, Ecuador.
ORCID-Profile: Arianna Mayorga-Ramos
Zitieren
APA
Mayorga-Ramos, A., Zúñiga-Miranda, J., Carrera-Pacheco, S. E., Barba-Ostria, C., & Guamán, L. P. (2023). CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance. ACS Infectious Diseases, 9(7), 1283-1302. https://doi.org/10.1021/acsinfecdis.2c00649
Vancouver
Mayorga-Ramos A, Zúñiga-Miranda J, Carrera-Pacheco SE, Barba-Ostria C, Guamán LP. CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance. ACS Infectious Diseases. 2023;9(7):1283-1302. doi:10.1021/acsinfecdis.2c00649
BibTeX
@article{MayorgaRamos2023,
author = {Mayorga-Ramos, Arianna and Zúñiga-Miranda, Johana and Carrera-Pacheco, Saskya E and Barba-Ostria, Carlos and Guamán, Linda P},
title = {CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance},
journal = {ACS Infectious Diseases},
year = {2023},
volume = {9},
number = {7},
pages = {1283--1302},
doi = {10.1021/acsinfecdis.2c00649}
}
EUVIMED